[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovarian-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovarian-adenocarcinoma":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,63,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":41,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100644985","clonal-hematopoiesis-chemotherapy-and-radiation-effects-study-100644985",false,"NCT07675967","Clonal Hematopoiesis Chemotherapy and Radiation Effects Study","CH CARE","Inclusion Criteria:\n\n* Participants to be included in this study include the following:\n* Adults age \\>18 years\n* Diagnosed with solid malignancy (breast, ovarian, lung, gastric, colorectal, esophageal, uterine, head and neck, or sarcoma cancers)\n* Have a pending plan to receive chemotherapy or radiation for their solid malignancy (cancer).\n* Has not received cytotoxic chemotherapy or radiation for their solid cancer diagnosis in the past.\n\nExclusion Criteria:\n\n* Individuals without plans for cytotoxic chemotherapy, radiation or PARP inhibitor exposure\n* Individuals who have received prior chemotherapy and or radiation for their current solid malignancy (cancer)\n* Individuals with any prior history of blood cancer (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, including smoldering multiple myeloma). Persons with blood cancer precursors including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of uncertain significance (CCUS), monoclonal B lymphocytosis (MBL), monoclonal gammopathy of uncertain significance (MGUS) are eligible for study participation.","ALL","18 Years",{"count":19,"type":20},5000,"ESTIMATED","OBSERVATIONAL","The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers.\n\nThe study will collect biospecimens and clinical information. These data will be used to define clinical and molecular features that predict the presence of high-risk clonal hematopoiesis (CH) in patients exposed to cytotoxic anti-cancer therapy. Predictive features will be utilized to identify populations of cancer patients and survivors who are at the highest risk of developing therapy-related myeloid neoplasms (t-MNs).\n\nUltimately this study will result in the development of a novel novel risk prediction algorithm for t-MNs in patients with solid cancers and drive potential therapeutic approaches to intercept progression from CH to often fatal t-MNs.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Lung Cancer (Diagnosis)","Osteochondroma","Spitz Nevus","Solid Cancers","Breast Cancer","Gastric (Stomach) Cancer","Colorectal (Colon or Rectal) Cancer","Sarcoma","Ovarian Adenocarcinoma","Uterine Adenocarcinoma","Endometrial Adenocarcinoma","Esophageal Adenocarcinoma","Head and Neck Cancer","Therapy-Related Acute Myeloid Leukemia","Therapy-Related MDS","Clonal Hematopoiesis of Indeterminate Potential (CHIP)","Clonal Cytopenia of Undetermined Significance",[42,43,44,45,46,47,48,49],"Adult cancer survivors","Precursor Lesions","clonal hematopoiesis","chemotherapy","radiation","therapy-related myeloid neoplasms","CCUS","clonal hematopoiesis of indeterminate potential","RECRUITING","2026-06-29",{"date":53,"type":54},"2026-06-30","ACTUAL",{"date":56,"type":54},"2025-04-04",{"date":58,"type":20},"2035-03-31",{"name":60,"class":61},"Dana-Farber Cancer Institute","OTHER",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":62},"100625965","assessment-of-adherence-to-remotely-monitored-physical-activity-tracked-on-a-smartwatch-and-its-impact-on-reducing-fatigue-3-months-after-adjuvant-chemotherapy-for-cancer-100625965","NCT07429487","Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer","WATCH AND ACT","Inclusion Criteria:\n\n1. Patients aged 18 to 75 years old,\n2. Histologically proven non-metastatic adenocarcinoma of breast, colorectal, ovarian, pancreatic, biliary, or gastric origin,\n3. Adjuvant chemotherapy completed less than 3 months ago (excluding hormone therapy),\n4. PS 0 or 1 according to the World Health Organization (WHO) scale,\n5. No recurrence since the end of adjuvant chemotherapy,\n6. Patient who has voluntarily agreed to participate in the study and sign the written informed consent form,\n7. Patient affiliated with a Social Security scheme.\n\nExclusion Criteria:\n\n1. New cancer treatment planned (excluding hormone therapy),\n2. Patient who has received adjuvant immunotherapy,\n3. Cardiological contraindication to the program\n4. Decompensated or unstable chronic conditions\n5. Severe malnutrition\n6. Rheumatological unfitness as determined by the oncologist,\n7. Chronic respiratory failure requiring long-term O2 therapy\n8. Diabetes with plantar ulceration\n9. Progressive or chronic non-healing bedsore\u002Fwound\n10. Recent unhealed fracture\n11. Patient participating in another interventional clinical study at the time of signing the informed consent form.\n12. Vulnerable persons as defined in Articles L1121-5 to -8","75 Years",{"count":72,"type":20},98,"INTERVENTIONAL",[75],"NA","A single-center, randomized (1:1) open-label, prospective, stratified study with two parallel arms, designed to evaluate adherence to the adapted physical activity (APA) program for patients participating in an APA program and to compare changes in fatigue at 3 months in patients who have completed adjuvant systemic chemotherapy for cancer and are participating in an APA program.",[28,78,32,79,80],"Colorectal Cancer","Pancreatic Cancer","Gastric Adenocarcinoma",[82,83,84],"adapted physical activity","fatigue","completed adjuvant systemic chemotherapy for cancer","NOT_YET_RECRUITING","2026-02-17",{"date":88,"type":54},"2026-02-24",{"date":90,"type":20},"2026-06-15",{"date":92,"type":20},"2030-06-15",{"name":94,"class":61},"Centre Antoine Lacassagne",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":102,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":105,"studyType":21,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":62},"100600653","anatomopathological-analysis-of-the-infundibulopelvic-ligament-in-patients-with-ovarian-cancer-100600653","NCT07100288","Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer","INFPELV","Inclusion Criteria:\n\n* ◦ Patients with epithelial ovarian cancer, including high- and low-grade serous, high- and low-grade endometrioid, mucinous (expansile and infiltrative types), and carcinosarcoma.\n\n  * FIGO 2014 stage IA-IVB.\n  * Patients undergoing primary surgery or interval surgery after 3-4 or 6 cycles of chemtherapy\n  * Patients with no residual disease after surgery.\n  * Patients with ECOG performance status 0-1.\n\nExclusion Criteria:\n\n* ◦ Patients without epithelial ovarian cancer.\n\n  * Patients with ECOG 2-4.\n  * Patients who do not consent to participate in the study.\n  * Patients who did not undergo complete staging surgery (including hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, and omentectomy) or with residual disease after cytoreductive surgery.","FEMALE",{"count":104,"type":20},200,"2 Years","Involvement of the infundibulopelvic ligament in ovarian cancer may be associated with decreased survival and related to paraaortic lymph node metastasis",[108,109,32],"Ovarian Cancer","Ovarian Cancer (OvCa)","2025-07-27",{"date":112,"type":54},"2025-08-03",{"date":114,"type":54},"2025-07-20",{"date":116,"type":20},"2030-12-30",{"name":118,"class":61},"Complejo Hospitalario Universitario Insular Materno Infantil"]